lucinogen use disorder with hallucinogen-induced  psychotic disorder or F16.259 for a
moderate or severe hallucinogen use disorder  with hallucinogen-induced psychotic disorder.
Specify current severity:
305.30 (F16.10) Mild:  Presence of 2–3 symptoms.
304.50 (F16.20) Moderate: Presence of 4–5 symptoms.
304.50 (F16.20) Severe:  Presence of 6 or more symptoms.
Specifiers
“In a controlled environment” app lies as a further specifier of remission if the individual is
both in remission and in a controlled environm ent (i.e., in early remission in a controlled
environment or in sustained remission in a controlled environmen t). Examples of these
environments are closely supe rvised and substanc e-free jails, therapeutic communities,
and locked hospital units. 
Diagnostic Features 
Hallucinogens comprise a diverse group of subs tances that, despite ha ving different chem-
ical structures and possibly involving diffe rent molecular mechan isms, produce similar
alterations of percepti on, mood, and cognition in users. Hallucinogens included are phenyl-
alkylamines (e.g., mescaline, DOM [2,5-d imethoxy-4-methylam phetamine], and MDMA
[3,4-methylenedioxymethamphetamine; also called “ecstasy ”]); the indoleamines, includ-
ing psilocybin (i.e., psilocin) and dimethyltryptamine (DMT); an d the ergolines, such as LSD
(lysergic acid diethylamide) and morning glory seeds. In addition, miscellaneous other